HHS sets “most favoured nation” pricing targets for drug makers
Drug manufacturers will now have to commit to the new pricing model to avoid regulatory action in the US.
Business & Regulation
Regeneron buys bankrupt 23andMe for $256m
Novo Nordisk’s CEO to step down as weight loss market share plummets
FDA biosimilar approvals set for record-breaking year amid US pricing reforms
Abeona secures cash runway with $155m priority review voucher sale
Q1 earnings pulse check: companies tentative on pharma-specific tariffs
Biogen’s Q1 revenue soars past estimates as rare disease pivot pays off
Big pharma pushes for European policy change as tariffs loom
